FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058849391> ?p ?o ?g. }

• W2058849391 endingPage "99" @default.
• W2058849391 startingPage "99" @default.
• W2058849391 abstract "Supportive care with blood products is still the mainstay of therapy for anemia occurring in patients with myelodysplastic syndromes (MDS). Recently, recombinant DNA technology has enabled us to develop erythropoietin as a therapeutic agent, and a few published studies have already assessed the clinical effects of the administration of recombinant human erythropoietin (r-HuEPO) to patients with MDS. In a first pilot study, two patients with refractory anemia (RA) were treated with r-HuEPO, administered i.v. with an initial dose of 50 U/kg body weight (bw) three times per week up to a maximum dose of 500 U/kg bw three times per week. In one case a good clinical response was achieved by the administration of r-HuEPO at the maximum dose. In another study, r-HuEPO at the doses of 3,000 to 12,000 U three times a week was administered i.v. for at least four weeks to 8 patients with MDS, observing some good clinical responses in three of them. The same authors confirmed response to r-HuEPO in 8 out of 33 patients in a larger multicenter study. More recently, 5 clinical responses to r-HuEPO were reported among 12 patients with MDS treated with escalating doses of 600 up to 3,000 U/kg bw per week. These results have not been confirmed by another phase I1 study, in which in 12 patients with MDS and anemia, r-HuEPO was given subcutaneously three times a week at doses ranging between 50 to 250 U/kg bw without any clinical effect. Finally in a recent randomized, placebo-controlled, double-blind trial, 20 patients with RA and RARS were treated with pharmacologic doses of r-HuEPO ranging between 1,200 to 1,600U/kg i.v. twice weekly, with overall responses occurring in 4 of 17 (24%) of evaluable patients. In all the above studies, r-HuEPO was well tolerated and no serious side effects were seen, even when very high doses of r-HuEPO were used. When the responders were compared to nonresponders, no clear difference was found between the two groups with respect to age, gender, diagnosis and time since diagnosis or previous treatment. Interestingly enough, response to r-HuEPO has not been significantly related to baseline serum erythropoietin concentration, indicating that the preliminary assessment of this parameter does not predict the clinical response to r-HuEPO. In conclusion, available data indicate that r-HuEPO administration is an effective treatment for a certain number of MDS patients; its clinical use, even at very high doses, has been shown to be safe and without any relevant side-effect. However, the criteria for response to r-HuEPO therapy, as well as the indication for therapy, remain to be clarified." @default.
• W2058849391 created "2016-06-24" @default.
• W2058849391 creator A5000767355 @default.
• W2058849391 creator A5003509028 @default.
• W2058849391 date "1992-01-01" @default.
• W2058849391 modified "2023-09-25" @default.
• W2058849391 title "Clinical Use of Recombinant Human Erythropoietin in the Treatment of Myelodysplastic Syndromes" @default.
• W2058849391 doi "https://doi.org/10.3109/10428199209058677" @default.
• W2058849391 hasPublicationYear "1992" @default.
• W2058849391 type Work @default.
• W2058849391 sameAs 2058849391 @default.
• W2058849391 citedByCount "0" @default.
• W2058849391 crossrefType "journal-article" @default.
• W2058849391 hasAuthorship W2058849391A5000767355 @default.
• W2058849391 hasAuthorship W2058849391A5003509028 @default.
• W2058849391 hasConcept C104317684 @default.
• W2058849391 hasConcept C126322002 @default.
• W2058849391 hasConcept C143998085 @default.
• W2058849391 hasConcept C203014093 @default.
• W2058849391 hasConcept C2778248108 @default.
• W2058849391 hasConcept C2778534260 @default.
• W2058849391 hasConcept C2780007613 @default.
• W2058849391 hasConcept C2780817109 @default.
• W2058849391 hasConcept C40767141 @default.
• W2058849391 hasConcept C502942594 @default.
• W2058849391 hasConcept C54355233 @default.
• W2058849391 hasConcept C71924100 @default.
• W2058849391 hasConcept C86803240 @default.
• W2058849391 hasConceptScore W2058849391C104317684 @default.
• W2058849391 hasConceptScore W2058849391C126322002 @default.
• W2058849391 hasConceptScore W2058849391C143998085 @default.
• W2058849391 hasConceptScore W2058849391C203014093 @default.
• W2058849391 hasConceptScore W2058849391C2778248108 @default.
• W2058849391 hasConceptScore W2058849391C2778534260 @default.
• W2058849391 hasConceptScore W2058849391C2780007613 @default.
• W2058849391 hasConceptScore W2058849391C2780817109 @default.
• W2058849391 hasConceptScore W2058849391C40767141 @default.
• W2058849391 hasConceptScore W2058849391C502942594 @default.
• W2058849391 hasConceptScore W2058849391C54355233 @default.
• W2058849391 hasConceptScore W2058849391C71924100 @default.
• W2058849391 hasConceptScore W2058849391C86803240 @default.
• W2058849391 hasIssue "sup2" @default.
• W2058849391 hasLocation W20588493911 @default.
• W2058849391 hasOpenAccess W2058849391 @default.
• W2058849391 hasPrimaryLocation W20588493911 @default.
• W2058849391 hasRelatedWork W1975591351 @default.
• W2058849391 hasRelatedWork W2042123351 @default.
• W2058849391 hasRelatedWork W2148240666 @default.
• W2058849391 hasRelatedWork W2159207341 @default.
• W2058849391 hasRelatedWork W2259235546 @default.
• W2058849391 hasRelatedWork W2303842901 @default.
• W2058849391 hasRelatedWork W2362045455 @default.
• W2058849391 hasRelatedWork W2433294562 @default.
• W2058849391 hasRelatedWork W4253113983 @default.
• W2058849391 hasRelatedWork W2187879833 @default.
• W2058849391 hasVolume "7" @default.
• W2058849391 isParatext "false" @default.
• W2058849391 isRetracted "false" @default.
• W2058849391 magId "2058849391" @default.
• W2058849391 workType "article" @default.